Infrastructure resilience

Join us at 11am on Wednesday 30th of June for a showcase of a number of research areas and technologies that address critical elements across different aspects

Learn more and register!

Technology Licensing opportunities

Available technologies

Clear search
High-resolution transcription start site mapping using nanogram-levels of total RNA immunoprecipitation (SLIC-CAGE)

SLIC-CAGE is a novel development of the cap-trapper CAGE protocol which can generate complex high-quality libraries for as little as 5-10 nanograms of cellular RNA.

Octreotate Radioligand for Imaging Neuroendocrine Tumors

18F-FET-βAG-TOCA is a novel, ‘click’ 18F-labelled octreotate PET imaging radiopharmaceutical that detects tumour lesions in patients with neuroendocrine tumours (NETs).

Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity

Two-gene signature diagnostic test for differentiating between viral and bacterial infections in children

A simple, whole blood 2-gene expression signature that distinguishes bacterial infection from both viral infection and childhood inflammatory diseases.

First-in-class drug candidate for treatment of multiple myeloma and Diffuse Large B Cell Lymphoma

DTP3 is a first-in-class GADD45β/MKK7 inhibitor targeting the NF-κB pathway

Novel apoptosis marker

A novel tracer, 18F-ICMT-11, targeting specific biological processes to improve detection of tumours that are often missed by FDG PET imaging

Advanced humidifier device

A novel, high capacity humidifying device which can rapidly humidify large spaces in seconds with multiple applications, including humidification and air purification.

Machine learning tool stratifying early and late Alzheimer's disease (ApV)

A tool for predicting Alzheimer’s Disease (AD) with greater accuracy than conventional methods.

Human monoclonal antibodies to COVID-19

The invention herein refers to a suite of broad neutralising monoclonal antibodies (bnMABs) isolated to be used for treatment of coronaviruses with a focus on SARS-CoV-2 (2019-nCoV). Four potential human monoclonal antibodies have been identified with broad neutralising activitiesin coronavirus(SARS and MERS).

Deep learning cardiac motion analysis for risk stratification of adverse cardiac event

A tool for predicting risk profile in patients with pre-existing cardiac dysfunction with greater accuracy than the current gold standard

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London